STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

最近更新时间: 16 Feb, 9:42AM

16.10

-0.39 (-2.37%)

前收盘价格 16.49
收盘价格 16.52
成交量 805,650
平均成交量 (3个月) 1,407,739
市值 794,791,872
预期市盈率 (P/E Forward) 48.78
价格/销量 (P/S) 3.90
股市价格/股市净资产 (P/B) 2.71
52周波幅
14.69 (-8%) — 30.81 (91%)
利润日期 17 Feb 2026
营业毛利率 -25.46%
营业利益率 (TTM) -81.43%
稀释每股收益 (EPS TTM) -1.44
季度收入增长率 (YOY) -44.90%
季度盈利增长率 (YOY) 107.20%
总债务/股东权益 (D/E MRQ) 10.48%
流动比率 (MRQ) 4.78
营业现金流 (OCF TTM) -11.69 M
杠杆自由现金流 (LFCF TTM) 10.73 M
资产报酬率 (ROA TTM) -5.90%
股东权益报酬率 (ROE TTM) -19.14%

市场趋势

短期 中期
行业 Medical Instruments & Supplies (US) 混合的 混合的
Medical Instruments & Supplies (全球的) 混合的 看跌
股票 STAAR Surgical Company 看跌 看涨

AIStockmoo 评分

-0.5
分析师共识 -0.5
内部交易活动 NA
价格波动 0.5
技术平均移动指标 -2.5
技术振荡指标 0.5
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
STAA 795 M - - 2.71
MMSI 4 B - 32.84 2.56
LMAT 2 B 0.79% 46.29 6.25
ATRC 2 B - - 3.02
AZTA 1 B - 46.52 0.610
PLSE 970 M - - 18.18

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

部门 Healthcare
行业 Medical Instruments & Supplies
投资方式 Small Growth
内部持股比例 0.64%
机构持股比例 109.43%

所有权

姓名 日期 持有股份
Sand Grove Capital Management Llp 30 Sep 2025 829,123
Defender Capital, Llc. 31 Dec 2025 668,222
Water Island Capital Llc 30 Sep 2025 658,317
52周波幅
14.69 (-8%) — 30.81 (91%)
目标价格波幅
16.00 (-0%) — 26.00 (61%)
26.00 (Wedbush, 61.49%) 保留
21.50 (33.54%)
16.00 (Wells Fargo, -0.62%) 保留
平均值 20.70 (28.57%)
总计 1 购买, 4 保留
平均价格@调整类型 19.21
公司 日期 目标价格 调整类型 价格@调整类型
Wells Fargo 05 Mar 2026 16.00 (-0.62%) 保留 18.57
Stifel 04 Mar 2026 18.00 (11.80%) 保留 19.22
09 Feb 2026 19.00 (18.01%) 保留 17.41
Wedbush 03 Feb 2026 26.00 (61.49%) 保留 18.15
Jefferies 28 Jan 2026 21.50 (33.54%) 购买 19.15
Canaccord Genuity 16 Jan 2026 22.00 (36.65%) 保留 20.97

该时间范围内无数据。

日期 类型 细节
02 Feb 2026 公告 STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
15 Jan 2026 公告 STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
06 Jan 2026 公告 Alcon Terminates Agreement to Acquire STAAR Surgical
06 Jan 2026 公告 Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
06 Jan 2026 公告 STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
19 Dec 2025 公告 Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
19 Dec 2025 公告 Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
17 Dec 2025 公告 Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
17 Dec 2025 公告 Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
17 Dec 2025 公告 STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
16 Dec 2025 公告 Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
16 Dec 2025 公告 Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
16 Dec 2025 公告 Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票